Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Recruiting

Phase 3

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Sponsor:

Johns Hopkins University

Code:

NCT04039464

Conditions

Pediatric Pulmonary Hypertension

Eligibility Criteria

Sex: All

Age: 3 - 18

Healthy Volunteers: Not accepted

Interventions

Mono-Therapy with Sildenafil

Duo-Therapy with Sildenafil + Bosentan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2024-10-15.